162 related articles for article (PubMed ID: 33486672)
1. Signaling pathways in human osteoclasts differentiation: ERK1/2 as a key player.
Pennanen P; Kallionpää RA; Peltonen S; Nissinen L; Kähäri VM; Heervä E; Peltonen J
Mol Biol Rep; 2021 Feb; 48(2):1243-1254. PubMed ID: 33486672
[TBL] [Abstract][Full Text] [Related]
2. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
3. Piperine alleviates osteoclast formation through the p38/c-Fos/NFATc1 signaling axis.
Deepak V; Kruger MC; Joubert A; Coetzee M
Biofactors; 2015; 41(6):403-13. PubMed ID: 26627060
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer-derived factors stimulate osteoclastogenesis through the Ca2+/protein kinase C and transforming growth factor-beta/MAPK signaling pathways.
Tiedemann K; Hussein O; Sadvakassova G; Guo Y; Siegel PM; Komarova SV
J Biol Chem; 2009 Nov; 284(48):33662-70. PubMed ID: 19801662
[TBL] [Abstract][Full Text] [Related]
5. CaMKII(δ) regulates osteoclastogenesis through ERK, JNK, and p38 MAPKs and CREB signalling pathway.
Lu DZ; Dong W; Feng XJ; Chen H; Liu JJ; Wang H; Zang LY; Qi MC
Mol Cell Endocrinol; 2020 May; 508():110791. PubMed ID: 32173349
[TBL] [Abstract][Full Text] [Related]
6. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.
Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW
Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020
[TBL] [Abstract][Full Text] [Related]
7. PDK1 is important lipid kinase for RANKL-induced osteoclast formation and function via the regulation of the Akt-GSK3β-NFATc1 signaling cascade.
Xiao D; Zhou Q; Gao Y; Cao B; Zhang Q; Zeng G; Zong S
J Cell Biochem; 2020 Nov; 121(11):4542-4557. PubMed ID: 32048762
[TBL] [Abstract][Full Text] [Related]
8. Constant hypoxia inhibits osteoclast differentiation and bone resorption by regulating phosphorylation of JNK and IκBα.
Ma Z; Yu R; Zhao J; Sun L; Jian L; Li C; Liu X
Inflamm Res; 2019 Feb; 68(2):157-166. PubMed ID: 30604211
[TBL] [Abstract][Full Text] [Related]
9. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation.
Lee SE; Woo KM; Kim SY; Kim HM; Kwack K; Lee ZH; Kim HH
Bone; 2002 Jan; 30(1):71-7. PubMed ID: 11792567
[TBL] [Abstract][Full Text] [Related]
10. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M
J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570
[TBL] [Abstract][Full Text] [Related]
11. Ameloblastin modulates osteoclastogenesis through the integrin/ERK pathway.
Lu X; Ito Y; Atsawasuwan P; Dangaria S; Yan X; Wu T; Evans CA; Luan X
Bone; 2013 May; 54(1):157-168. PubMed ID: 23385480
[TBL] [Abstract][Full Text] [Related]
12. miR‑21 promotes osteoclastogenesis through activation of PI3K/Akt signaling by targeting Pten in RAW264.7 cells.
Wang S; Liu Z; Wang J; Ji X; Yao Z; Wang X
Mol Med Rep; 2020 Mar; 21(3):1125-1132. PubMed ID: 32016444
[TBL] [Abstract][Full Text] [Related]
13. P38 mitogen-activated protein kinase inhibitor, FR167653, inhibits parathyroid hormone related protein-induced osteoclastogenesis and bone resorption.
Tao H; Okamoto M; Nishikawa M; Yoshikawa H; Myoui A
PLoS One; 2011; 6(8):e23199. PubMed ID: 21886782
[TBL] [Abstract][Full Text] [Related]
14. Cafestol has a weaker inhibitory effect on osteoclastogenesis than kahweol and promotes osteoblast differentiation.
Fukuma Y; Sakai E; Nishishita K; Okamoto K; Tsukuba T
Biofactors; 2015; 41(4):222-31. PubMed ID: 26154488
[TBL] [Abstract][Full Text] [Related]
15. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
16. Low-density lipoprotein receptor deficiency causes impaired osteoclastogenesis and increased bone mass in mice because of defect in osteoclastic cell-cell fusion.
Okayasu M; Nakayachi M; Hayashida C; Ito J; Kaneda T; Masuhara M; Suda N; Sato T; Hakeda Y
J Biol Chem; 2012 Jun; 287(23):19229-41. PubMed ID: 22500026
[TBL] [Abstract][Full Text] [Related]
17. Kalkitoxin Reduces Osteoclast Formation and Resorption and Protects against Inflammatory Bone Loss.
Li L; Yang M; Shrestha SK; Kim H; Gerwick WH; Soh Y
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669069
[TBL] [Abstract][Full Text] [Related]
18. Ameloblastin attenuates RANKL-mediated osteoclastogenesis by suppressing activation of nuclear factor of activated T-cell cytoplasmic 1 (NFATc1).
Chaweewannakorn W; Ariyoshi W; Okinaga T; Fujita Y; Maki K; Nishihara T
J Cell Physiol; 2019 Feb; 234(2):1745-1757. PubMed ID: 30105896
[TBL] [Abstract][Full Text] [Related]
19. The calcium channel TRPV6 is a novel regulator of RANKL-induced osteoclastic differentiation and bone absorption activity through the IGF-PI3K-AKT pathway.
Ma J; Zhu L; Zhou Z; Song T; Yang L; Yan X; Chen A; Ye TW
Cell Prolif; 2021 Jan; 54(1):e12955. PubMed ID: 33159483
[TBL] [Abstract][Full Text] [Related]
20. Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade.
Moon JB; Kim JH; Kim K; Youn BU; Ko A; Lee SY; Kim N
J Immunol; 2012 Jan; 188(1):163-9. PubMed ID: 22131333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
